Clinical Assessment Methods Flashcards

A 68-year-old patient with CKD stage 3b (eGFR 38 mL/min/1.73m²) presents with a serum creatinine of 148 µmol/L. His serum cystatin C is markedly elevated relative to what would be predicted by creatinine alone. Which clinical scenario BEST explains this discordance?

Answer: The patient has significant sarcopenia reducing creatinine generation

Serum creatinine is a product of muscle metabolism; significant sarcopenia (muscle wasting) leads to reduced creatinine generation, causing creatinine-based eGFR equations (CKD-EPI, MDRD) to overestimate true GFR. Cystatin C is produced at a constant rate by all nucleated cells and is independent of muscle mass, making it a more accurate GFR marker in patients with sarcopenia. Corticosteroids actually increase cystatin C levels (not decrease), high-protein meals affect urea more than creatinine acutely, and hypothyroidism does not reduce tubular creatinine secretion.

During a medication therapy management visit, you assess a patient's adherence using the Morisky Medication Adherence Scale (MMAS-8). The patient scores 6 out of 8. When interpreting this result to guide clinical action, which limitation of this tool is MOST critical to acknowledge?

Answer: Self-report bias leads to systematic overestimation of adherence; a score of 6 may reflect lower true adherence than indicated

The MMAS-8 is a self-report tool subject to social desirability bias — patients systematically overreport adherence. A score of 6/8 places the patient in the 'medium adherence' category (scores ≥ 8 = high, 6–7 = medium, < 6 = low), but the actual adherence is likely lower than reported. This is the most clinically critical limitation when deciding intervention intensity. The MMAS-8 does capture both intentional and unintentional non-adherence types across its items, and it is used in Canadian practice research.

A pharmacist is performing a comprehensive pain assessment using the Brief Pain Inventory (BPI) in a palliative care patient receiving scheduled hydromorphone. The patient rates pain severity as 3/10 but pain interference with general activity as 8/10. Which pharmacist action reflects the MOST clinically appropriate interpretation of this discordance?

Answer: Recognize that functional interference may reflect opioid-induced sedation or other symptoms beyond pain, and conduct a broader symptom assessment

A high pain interference score with low pain severity in a palliative patient on opioids raises the possibility that interference with activity is driven by opioid adverse effects (e.g., sedation, constipation, cognitive impairment) or comorbid symptoms (dyspnea, fatigue) rather than undertreated pain. The BPI captures two distinct constructs: severity and functional interference. Immediately escalating opioids based solely on interference could worsen opioid-related harms. A broader symptom assessment (using tools like the Edmonton Symptom Assessment System) is the appropriate next step.

Which of the following represents a STAGE C classification in the ACC/AHA Heart Failure staging system, and what is its key distinction from Stage B?

Answer: Structural heart disease with prior or current symptoms of heart failure; distinguished from Stage B by the presence of symptoms

ACC/AHA Stage C is defined as structural heart disease WITH prior or current symptoms of heart failure (e.g., dyspnea, fatigue, reduced exercise tolerance). The critical distinction from Stage B is the presence of symptoms — Stage B patients have structural heart disease (e.g., reduced EF, LVH, previous MI) but have never experienced HF symptoms. This staging system is progression-based and does not regress; a patient who has had symptoms remains Stage C even if currently asymptomatic on optimal therapy. Stage D is the refractory/advanced stage.

A clinical pharmacist is assessing nutritional status in an ICU patient using the Subjective Global Assessment (SGA). The patient has lost 12% of body weight over 3 months, has mild ankle edema, and diminished subcutaneous fat over the triceps with moderate muscle wasting at the temples. Dietary intake has been inadequate for 3 weeks. Based on SGA methodology, which rating is MOST appropriate?

Answer: SGA-B (moderately malnourished or suspected malnutrition) based on functional and physical findings

SGA-B (moderately/suspected malnourished) is appropriate here. SGA integrates weight change, dietary intake, GI symptoms, functional capacity, and physical exam findings (subcutaneous fat, muscle wasting, edema). Weight loss of 12% over 3 months is significant, but the physical findings (mild, not severe muscle wasting; diminished but not absent subcutaneous fat) and edema do not meet the threshold for SGA-C. SGA-C requires severe losses across multiple domains. Importantly, SGA does NOT use a single cutoff (e.g., >10% weight loss) to assign a category — it is a composite clinical judgment. While NUTRIC scores are used in ICU for nutrition risk, SGA remains applicable in this setting.

When applying the CAGE-AID questionnaire to screen for concurrent alcohol and drug use disorders, a patient answers 'yes' to the 'Eye-opener' question specifically in the context of cannabis use to manage morning anxiety. Which statement BEST reflects the pharmacist's appropriate clinical interpretation?

Answer: One 'yes' response meets the threshold for a positive screen (≥1) in some validated cut-offs, but further structured assessment is needed to characterize the clinical significance and functional impact

The CAGE-AID is a brief screening tool adapted from CAGE to include drugs. A cut-off of ≥1 'yes' answer is used in some studies for higher sensitivity (particularly for drugs other than alcohol), while ≥2 is the traditional alcohol cut-off. A single positive response is a positive screen at ≥1 threshold — but screening tools identify who needs further assessment, not who has a confirmed disorder. A single 'Eye-opener' response warrants structured follow-up using diagnostic criteria (DSM-5) or a more comprehensive instrument (e.g., AUDIT-C, DAST-10, or a full clinical interview). Cannabis can produce physiological dependence, and the Eye-opener item is valid — using a substance first thing in the morning to manage withdrawal or craving is clinically significant.